• SSY Group products were added to China’s National Essential Medicines List (2026 edition), covering 95 product types across 141 specifications.
• The list takes effect Sept. 1, 2026, supporting expected growth and business expansion.
• New inclusions include several injectables, antibiotics, and respiratory therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12240557), on July 10, 2026, and is solely responsible for the information contained therein.